- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | Needham raises MapLight Therapeutics stock price target on trial data | 1 | Investing.com | ||
| 25.06. | Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts | 3 | Seeking Alpha | ||
| MAPLIGHT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.06. | Raymond James initiates MapLight stock with strong buy on drug trial | 1 | Investing.com | ||
| 24.06. | MapLight Therapeutics beruft zwei neue Direktoren in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| 24.06. | MapLight Therapeutics, Inc.: MapLight Therapeutics Announces Changes to Board of Directors | 180 | GlobeNewswire (Europe) | SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering... ► Artikel lesen | |
| 23.06. | MapLight Therapeutics stock maintained at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 22.06. | MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents | 1 | Benzinga.com | ||
| 22.06. | H.C. Wainwright reiterates MapLight Therapeutics stock rating on muscarinic mechanism potential | 2 | Investing.com | ||
| 22.06. | MapLight Therapeutics Says IRIS Phase 2 Trial Did Not Meet Its Primary Endpoint; Stock Down 10.5% | 1 | RTTNews | ||
| 22.06. | MapLight Therapeutics, Inc.: MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder | 211 | GlobeNewswire (Europe) | The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A prespecified analysis in adolescents with moderate to severe baseline irritability (ABC-I... ► Artikel lesen | |
| 18.06. | MapLight Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | Stifel raises MapLight Therapeutics price target on drug potential | 1 | Investing.com | ||
| 01.06. | Stifel hebt Kursziel für MapLight Therapeutics wegen Medikamentenpotenzial an | 2 | Investing.com Deutsch | ||
| 21.05. | MapLight Therapeutics: Craig-Hallum startet Coverage mit Kaufempfehlung und 54 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| 21.05. | Craig-Hallum initiates MapLight Therapeutics stock with buy rating | 3 | Investing.com | ||
| 15.05. | MapLight Therapeutics, Inc. GAAP EPS of -$1.34 | 1 | Seeking Alpha | ||
| 14.05. | MapLight Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | MapLight completes enrollment in two phase 2 CNS trials | 2 | Investing.com | ||
| 01.05. | MapLight schließt Rekrutierung für zwei zentrale ZNS-Studien ab | 1 | Investing.com Deutsch | ||
| 01.05. | MapLight Therapeutics, Inc.: MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results | 280 | GlobeNewswire (Europe) | Enrollment completed in ML-007C-MA's ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004's IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,965 | -0,55 % | Qiagen: Die Gerüchte gehen in die zweite Runde | Im Januar wurde gemunkelt, Qiagen könnte unmittelbar vor einer Übernahme stehen. Doch am Ende verlief die Sache im Sand. Die Aktie, die damals einen Riesensatz nach oben gemacht hatte, fiel tiefer als... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,07 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 19,160 | +0,74 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,075 | +9,82 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,500 | -1,61 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,060 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,42 | 0,00 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| KYMERA THERAPEUTICS | 115,77 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,530 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,490 | +3,08 % | Mizuho hebt Kursziel für Tango Therapeutics nach vielversprechenden Studiendaten an | ||
| NURIX THERAPEUTICS | 23,120 | +0,22 % | Mizuho hebt Kursziel für Nurix nach Roche-Deal auf 34 US-Dollar an | ||
| ARRIVENT BIOPHARMA | 33,190 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,960 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| CG ONCOLOGY | 71,92 | +3,48 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 42,620 | +6,20 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP-... ► Artikel lesen |
MAPLIGHT THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 37,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAPLIGHT THERAPEUTICS INC finden Sie auf Wallstreet Online.